Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Purpose Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib
Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared …

Abstract Bosutinib, a dual Src/Abl kinase inhibitor, has shown potent activity against chronic
myeloid leukemia (CML). In this phase 1/2 study we evaluated bosutinib in patients with …

ABCG2, or breast cancer resistance protein (BCRP), is an ABC transporter that has been the
subject of intense study since its discovery a decade ago. With high normal tissue …

Although imatinib, a BCR-ABL tyrosine kinase inhibitor, is used to treat acute Philadelphia
chromosome–positive (Ph+) leukemia, it does not prevent central nervous system (CNS) …

Purpose Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against
unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with …

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

Background The FDA-approved small-molecule drug dasatinib is currently used as a
treatment for chronic myeloid leukemia (CML). However, the effects of dasatinib on …

Molecularly targeted cancer therapies, such as small-molecule kinase inhibitors and
monoclonal antibodies, constitute a rapidly growing and an important part of the oncology …